GU Cancers 2020 | ATLAS update: rucaparib for bladder cancer
VJOncology is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Petros Grivas, MD, PhD, University of Washington, Seattle, WA, outlines the ATLAS study (NCT03397394), which investigated the efficacy of the PARP inhibitor rucaparib in the treatment of urothelial carcinoma. This interview was recorded at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.
Get great new content delivered to your inboxSign up